Price$18.44-0.11 (-0.57%)
01:30 PM06:45 PM
News · 26 weeks72+27%
2025-12-282026-06-21
Mix4590d
- Insider25(56%)
- SEC Filings10(22%)
- Other7(16%)
- Earnings3(7%)
Latest news
25 items- INSIDERDirector Wirth Peter was granted 22,371 units of American Depositary Shares, increasing direct ownership by 6% to 416,121 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Diekman John D was granted 22,371 units of American Depositary Shares, increasing direct ownership by 22% to 122,140 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Morrison Scott W was granted 22,371 units of American Depositary Shares, increasing direct ownership by 65% to 56,904 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Moulder Leon O Jr was granted 22,371 units of American Depositary Shares, increasing direct ownership by 31% to 94,973 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Leung Nisa was granted 22,371 units of American Depositary Shares, increasing direct ownership by 30% to 96,297 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Gaynor Richard was granted 22,371 units of American Depositary Shares, increasing direct ownership by 40% to 79,001 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Vounatsos Michel was granted 22,371 units of American Depositary Shares, increasing direct ownership by 44% to 72,787 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERDirector Lis William was granted 22,371 units of American Depositary Shares, increasing direct ownership by 64% to 57,477 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- SECSEC Form 144 filed by Zai Lab Limited144 - Zai Lab Ltd (0001704292) (Subject)
- SECZai Lab Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) - SCLC is the most significant pulmonary neuroendocrine carcinoma (NEC), affecting an estimated 375,000 patients annually worldwide, with limited treatment options - EMA designation for zoci in pulmonary NECs closely follows receipt of Fast Track designation from the U.S. Food and Drug Administration for zoci in extrapulmonary neuroendocrine carcinomas (epNECs) and promising data presented at the AACR Annual Meeting in April
- PRZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China - TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the trial's China subpopulation Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This approval is based
- INSIDERSEC Form 4 filed by Operating Partner Wang Yizhe4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wang Yizhe3 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying gifted 107,700 units of American Depositary Shares, decreasing direct ownership by 9% to 1,158,583 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab Announces Changes to Senior Leadership TeamZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors," said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary
- SECZai Lab Limited filed SEC Form 8-K: Leadership Update8-K - Zai Lab Ltd (0001704292) (Filer)
- INSIDERChairperson & CEO Du Ying exercised 261,092 units of American Depositary Shares at a strike of $1.74 and covered exercise/tax liability with 117,435 units of American Depositary Shares, increasing direct ownership by 13% to 1,266,283 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $1,986,875 worth of American Depositary Shares (100,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Legal Officer Edmondson Frazor Titus Iii sold $71,008 worth of American Depositary Shares (3,517 units at $20.19) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 19,849 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $2,003,044 worth of American Depositary Shares (100,000 units at $20.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs - Zoci NEC clinical program is advancing toward registration, with active engagement with Health Authorities underway Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the tre
- SECSEC Form 10-Q filed by Zai Lab Limited10-Q - Zai Lab Ltd (0001704292) (Filer)
- SECZai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pelitecan (zoci) delivered standout data at AACR 2026, with a 62.5% confirmed intracranial ORR in SCLC patients with brain metastases, and clinically meaningful activity (38.2% confirmed ORR) across epNECs; registrational DLLEVATE trial ongoing with enrollment expected to complete in the first half of 2027 – Collaborations with Amgen and Boehringer Ingelheim to evaluate zoci in combination with tarlatamab in SCLC and obrixtamig in SCLC and other NECs, posi
ZLAB FAQ
7 questionsWhat does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer...Where does ZLAB stock trade?
Zai Lab Limited (ZLAB) is listed on NASDAQ.What sector and industry is ZLAB in?
Zai Lab Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zai Lab Limited go public?
Zai Lab Limited (ZLAB) completed its IPO in 2017.What are analysts saying about ZLAB?
Zai Lab Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-08-25. Recent price targets range from $3610.00 to $4750.00.What companies are similar to ZLAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZLAB side-by-side with any of them on Quantisnow.How can I track ZLAB on Quantisnow?
Quantisnow aggregates Zai Lab Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZLAB to receive live email and push alerts on every new disclosure.